Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2426985 | 1.00 | ALOX15 (0.47) | ALOX15DRD2KCNA3NSD2EPHX2 | |
| SCHEMBL2427157 | 0.88 | KCNA3 (0.43) | ALOX15DRD2KCNA3NSD2EPHX2 | |
| SCHEMBL2427152 | 0.88 | KCNA3 (0.43) | ALOX15DRD2KCNA3NSD2EPHX2 | |
| SCHEMBL2428995 | 0.87 | DRD2 (0.44) | DRD2KCNA3NSD2BTKTNF | |
| SCHEMBL2428992 | 0.87 | DRD2 (0.44) | DRD2KCNA3NSD2BTKTNF | |
| SCHEMBL23826087 | 0.85 | ALOX15 (0.49) | ALOX15DRD2EPHX2BTKMAPT | |
| SCHEMBL23826085 | 0.85 | ALOX15 (0.49) | ALOX15DRD2EPHX2BTKMAPT | |
| SCHEMBL23826603 | 0.85 | ALOX15 (0.49) | ALOX15DRD2EPHX2BTKMAPT | |
| SCHEMBL23826899 | 0.85 | ALOX15 (0.49) | ALOX15DRD2EPHX2BTKMAPT | |
| SCHEMBL23826600 | 0.85 | ALOX15 (0.49) | ALOX15DRD2EPHX2BTKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | ALOX15 1532/4885DRD2 206/4885KCNA3 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.